Basem William, MD, MRCP, FACP, discusses the preliminary results of the phase II trial of brentuximab vedotin and lenalidomide in relapsed/refractory cutaneous and peripheral T-cell lymphomas.
Basem William, MD, MRCP, FACP, associate professor of internal medicine, The Ohio State University, discusses the preliminary results of the phase II trial of brentuximab vedotin (Adcetris) and lenalidomide (Revlimid) in patients with relapsed/refractory cutaneous and peripheral T-cell lymphomas.
This trial, modeled after a prior trial in diffuse large B-cell lymphoma, initially gave patients 1.2 mg/kg of brentuximab vedotin and 20 mg of lenalidomide, explains William. However, an excessive tumor flare in the skin was seen and the lenalidomide dose was dropped to 10 mg after treating 7 patients, says William.
Most patients in the trial had heavily pretreated cutaneous T-cell lymphoma with a median 5 lines of prior therapy. Additionally, there was no required CD30 positivity. The overall response rate was 33%, according to William. The preliminary results report on 17 patients and the ongoing study's goal is 32 patients, concluded William.